clinical trial results

Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Does the Artery-first Approach Improve the Rate of R0 Resection in Pancreatoduodenectomy?: A Multicenter, Randomized, Controlled Trial Bookmark

Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

This clinical trial found no difference in tumor-free margins from standard versus artery-first surgical techniques for the resection of pancreatic head adenocarcinoma via pancreatoduodenectomy.

Go to full paper published in Annals of Surgery.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Combo Therapy Shows Modest Survival Gain, More Toxicity for Gastric Cancer Bookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

A clinical trial of a combination therapy for gastric cancer showed modest increased overall survival (OS) in one group of patients, but at the cost of increased adverse effects.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers Bookmark

Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

Go to full article published by Targeted Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

A clinical trial showed substantial benefits of progression-free survival and overall survival for patients with a particular form of acute myeloid leukemia when treated by gilteritinib versus chemotherapy. However, the disease was still fatal.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma Bookmark

Excerpt:

“A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be treated with anti–PD-1 drugs before surgery—also showed that immune responses brought on by this therapy can peak as early as 7 days after treatment—much earlier than previous studies have shown. These findings were published by Huang et al in Nature Medicine.”

Go to full article published by The ASCO Post on March 7, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Experimental Drug Helps Women With Deadly Type of Breast Cancer Bookmark

Excerpt:

“An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.

“Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.”

Go to full article published by U.S. News on Feb 20, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Aggressive RT, Surgery Doubles OS in NSCLC With Limited Mets Bookmark

Excerpt:

“Aggressive local consolidation in stage IV non-small lung cancer (NSCLC) drastically improved overall survival over standard care in patients with up to three metastatic lesions, a small randomized study found.

“Among 49 patients whose disease had not progressed after initial systemic therapy, overall survival was 41.2 months in those treated with radiotherapy or surgery compared with 17.0 months in those on standard maintenance therapy (P=0.017), reported Daniel Gomez, MD, of MD Anderson Cancer Center in Houston, at a press briefing here at the American Society for Radiation Oncology (ASTRO) meeting.”

Go to full article published by MedPage Today on Oct 22, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Novartis Drug Cut Death Risk by 35 Percent in Gene Mutation Breast Cancer Bookmark

Excerpt:

“An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.

“The Swiss drugmaker’s BYL719, a so-called PI3K inhibitor also known as alpelisib, combined with hormone therapy fulvestrant boosted median progression-free survival (PFS) to 11 months, up from 5.7 months for patients who got only hormone therapy, the company said on Saturday.”

Go to full article published by Reuters on Oct 20, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma Bookmark

Excerpt from MedPage Today:

“Combination neoadjuvant immune checkpoint blockade therapy yielded promising outcomes in high-risk resectable melanoma, although toxicity was an issue, according to a phase II trial.

“The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) led to improved progression-free survival (PFS), distant metastasis-free survival (DMFS), and overall survival (OS) versus neoadjuvant nivolumab monotherapy in 23 patients with high-risk resectable melanoma, reported Jennifer A. Wargo, MD, of MD Anderson Cancer Center in Houston, and colleagues in Nature Medicine.”

Go to full article published by MedPage Today on Oct 11, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.